Wildemann, Brigitte http://orcid.org/0000-0002-5389-3338
Jarius, Sven
Franz, Jonas
Ruprecht, Klemens
Reindl, Markus
Stadelmann, Christine
Funding for this research was provided by:
Dietmar Hopp Stiftung (23011211)
Bundesministerium für Forschung und Technologie (FKZ 01GI1602D)
Merck Serono
Austrian Science Fund (P32699)
Deutsche Forschungsgemeinschaft (EXC 2067/1- 390729940)
Gemeinnützige Hertie-Stiftung
Deutsche Multiple Sklerose Gesellschaft
National Multiple Sclerosis Society
Ruprecht-Karls-Universität Heidelberg
Article History
Received: 30 July 2020
Revised: 4 October 2020
Accepted: 5 October 2020
First Online: 19 October 2020
Compliance with ethical standards
:
: Brigitte Wildemann received grants from German Ministry of Education and Research, Deutsche Forschungsgemeinschaft, Dietmar Hopp Foundation, and Klaus Tschira Foundation, grants and personal fees from Merck Serono, Sanofi Genzyme, and Novartis pharmaceuticals, and personal fees from Bayer Healthcare, Biogen, Teva Pharma. Sven Jarius reports no conflicts of interest. Jonas Franz reports no conflicts of interest. Klemens Ruprecht received research support from Novartis, Merck Serono, German Ministry of Education and Research, European Union (821283-2), Stiftung Charité (BIH Clinical Fellow Program) and Arthur Arnstein Foundation; received speaker honoraria and travel grants from Bayer, Biogen Idec, Merck Serono, sanofi-aventis/Genzyme, Teva, Roche, Novartis, and Guthy Jackson Charitable Foundation. Markus Reindl reports the following conflicts of interest: The University Hospital and Medical University of Innsbruck (Austria; employer of MR) receives payments for antibody assays (MOG, AQP4 and other autoantibodies) and for MOG and AQP4 antibody validation experiments organized by Euroimmun (Lübeck, Germany). Markus Reindl is supported by a research grant from the Austrian Science Fund (FWF, project P32699). Christine Stadelmann has received research support from Novartis and Medday, speaker’s honoraria from Novartis and Roche and served on advisory boards of Merck Serono and Roche. No conflicts of interests with regard to the present work.
: The patient has given written consent to the publication of this case report.